Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.
Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.
Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214).
Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP.
J Clin Oncol. 2011 Mar 10;29(8):957-62. doi: 10.1200/JCO.2009.26.4655. Epub 2011 Jan 31.
Contemporary Role of Radiation Therapy in Testicular Cancer.
Shiao JC, Shen X.
Urol Clin North Am. 2024 Aug;51(3):395-405. doi: 10.1016/j.ucl.2024.03.008. Epub 2024 Apr 21.
Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de-implementation.
Skolarus TA, Caram ME, Chapman CH, Smith DC, Hollenbeck BK, Hawley S, Tsodikov A, Sales A, Wittmann D, Zaslavsky A.
Cancer. 2018 Oct 15;124(20):3971-3974. doi: 10.1002/cncr.31665. Epub 2018 Sep 7.
How do we define "castration" in men on androgen deprivation therapy?
Itty S, Getzenberg RH.
Asian J Androl. 2020 Sep-Oct;22(5):441-446. doi: 10.4103/aja.aja_139_19.
Castration-resistant prostate cancer: systemic therapy in 2012.
Maluf FC, Smaletz O, Herchenhorn D.
Clinics (Sao Paulo). 2012;67(4):389-94. doi: 10.6061/clinics/2012(04)13.
Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients with Prostate Cancer.
Kan WC, Hsieh KL, Chen YC, Ho CH, Hong CS, Chiang CY, Wu NC, Chen M, Shih JY, Chen ZC, Chang WT.
J Urol. 2022 Apr;207(4):841-850. doi: 10.1097/JU.0000000000002340. Epub 2021 Dec 2.
Double-layer omics analysis of castration- and X-ray-resistant prostate cancer cells.
Iwanaga M, Kawamura H, Kubo N, Mizukami T, Oike T, Sato H, Miyazawa Y, Sekine Y, Kawabata-Iwakawa R, Nishiyama M, Ohno T, Nakano T.
J Radiat Res. 2022 Jul 19;63(4):585-590. doi: 10.1093/jrr/rrac022.
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Pal SK, Sartor O.
Maturitas. 2011 Feb;68(2):103-5. doi: 10.1016/j.maturitas.2010.10.009. Epub 2010 Nov 19.
Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair.
Tarish FL, Schultz N, Tanoglidi A, Hamberg H, Letocha H, Karaszi K, Hamdy FC, Granfors T, Helleday T.
Sci Transl Med. 2015 Nov 4;7(312):312re11. doi: 10.1126/scitranslmed.aac5671.
